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MicroRNAs 143 and 150 in whole blood
enable detection of T-cell immunoparalysis
in sepsis
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Abstract
Background: Currently, no suitable clinical marker for detection of septic immunosuppression is available. We
aimed at identifying microRNAs that could serve as biomarkers of T-cell mediated immunoparalysis in sepsis.
Methods: RNA was isolated from purified T-cells or from whole blood cells obtained from septic patients and
healthy volunteers. Differentially regulated miRNAs were identified by miRNA Microarray (n = 7). Validation was
performed via qPCR (n = 31).
Results: T-cells of septic patients revealed characteristics of immunosuppression: Pro-inflammatory miR-150 and
miR-342 were downregulated, whereas anti-inflammatory miR-15a, miR-16, miR-93, miR-143, miR-223 and miR-424
were upregulated. Assessment of T-cell effector status showed significantly reduced mRNA-levels of IL2, IL7R and
ICOS, and increased levels of IL4, IL10 and TGF-β. The individual extent of immunosuppression differed markedly.
MicroRNA-143, − 150 and − 223 independently indicated T-cell immunoparalysis and significantly correlated with
patient’s IL7R-/ICOS-expression and SOFA-scores. In whole blood, composed of innate and adaptive immune cells,
both traits of immunosuppression and hyperinflammation were detected. Importantly, miR-143 and miR-150 – both
predominantly expressed in T-cells – retained strong power of discrimination also in whole blood samples.
Conclusions: These findings suggest miR-143 and miR-150 as promising markers for detection of T-cell
immunosuppression in whole blood and may help to develop new approaches for miRNA-based diagnostic in sepsis.
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Background
Sepsis has long been viewed as a disease with sequentially
proceeding phases of hyperinflammation and immunopar-
alysis. Currently, it has become increasingly clear that sep-
sis is more a complex syndrome than a disease: Recent
studies have indicated that states of hyperinflammation,
largely driven by innate immune cells, and immunosup-
pression, mainly affecting adaptive immunity, can occur at
any time, sequentially or even simultaneously (Boomer et
al. 2014; Xiao et al. 2011). Immunoparalysis, however, has
been identified as the major clinical problem leading to
death in a large number of patients (Boomer et al. 2011).
In this situation, effective tools for early detection and
consecutive monitoring of immunosuppression are lack-
ing, which reduces therapeutic.
success and hampers development of new strategies
targeting immune dysfunction. Commonly used bio-
markers in sepsis, e.g. C-reactive Protein, Interleukin-6,
and Procalcitonin, lack sensitivity and specificity and
cannot indicate immunosuppression (Samraj et al. 2013).
Very recent attempts to assess an impaired immune sta-
tus based on quantification of cell surface markers
(HLA-DR3) or mRNAs (IL-10, CD74) have not yet made
their way into clinical practice, as these strategies either
rely on flow cytometric analysis, which is technically
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highly demanding, or on quantification of mRNA tran-
scripts, which is always threatened by the mRNA’s in-
trinsic instability (Landelle et al. 2010; Peronnet et al.
2017). MiRNAs might bear the potential to fill this gap.
MicroRNAs are small non-coding RNAs acting as key
regulators in gene expression networks, thus playing a piv-
otal role in almost all cellular processes (Bartel 2009). By
base-pairing to the 3′-untranslated region (3’UTR) of their
respective target genes, miRNAs posttranscriptionally re-
press gene expression (Bartel 2004). MicroRNAs display
regulatory potential in a wide range of human diseases in-
cluding cardiovascular conditions, degenerative processes,
systemic inflammation and cancer (Pencheva and Tava-
zoie 2013; Hata 2013; Jung and Suh 2014; O'Connell et al.
2012; Hirschberger et al. 2018). In addition, identification
and validation of miRNAs as biomarkers is an emerging
field in medicine, given their tissue- and disease-specific
expression and high stability even when released into the
circulation (Weiland et al. 2012). In sepsis, recent publica-
tions reported altered expression of specific miRNAs. The
authors suggested individual or sets of miRNAs as bio-
markers to enable an early diagnosis, to differentiate dif-
ferent sepsis severity grades, and/or to predict survival
(reviewed in (Kreth et al. 2017)). Results of these studies,
however, were remarkably heterogeneous, and a consen-
sus with respect to actually suitable biomarkers has not
been reached so far. Disparate findings of these studies
were most likely due to varying study aims, small sample
sizes, and use of different sample types (either plasma/
serum or whole blood or peripheral blood mononuclear
cells) (Benz et al. 2016; Ho et al. 2016; Kingsley and Bhat
2017). The latter is of particular importance as different
blood cell types exhibit highly specific transcriptomes and,
naturally, differ considerably in miRNA expression profiles
(Ecker et al. 2017; Leidinger et al. 2014; Palmer et al.
2006). Taking into consideration the fact that innate and
adaptive immune cells may be regulated in a diametrically
opposed way during sepsis (Boomer et al. 2014; Xiao et al.
2011; Cavaillon and Annane 2006; Tang et al. 2010), a
more specific approach for the detection of immunosup-
pression is needed.
We hypothesized that specific miRNAs are capable to
detect and to characterize sepsis-associated immunopara-
lysis. As particularly lymphocytes represent the suppressed
adaptive immune response, we first set out to identify suit-
able miRNAs in T-cells and then – to facilitate clinical ap-
plication – transferred our findings to whole blood
samples. We here present a pilot study using miRNAs to
specifically assess immunosuppression in sepsis.
Methods
Blood sampling
After obtaining informed consent, blood samples were
withdrawn from healthy volunteers and from patients
diagnosed with either sepsis or septic shock (by fulfilling
the criteria SIRS + infection, according to the American
College of Chest Physicians/Society of Critical Care
Medicine consensus conference (Bone et al. 1992)).
Retrospective evaluation showed that all patients were
meeting the Sepsis-3 definitions (Singer et al. 2016). Pa-
tient analysis and microRNA evaluation was performed
between 2011 and 2017, controls have been sampled
from 2010 to 2016. For whole blood analysis a second,
independent patient/ control group was analysed. The
study protocol was approved by the Institutional Ethics
Committees of the Ludwig-Maximilian-University Mun-
ich, Germany (No. 107–11 and No. 287–13; approved in
2006), of the University Hospital of Jena (No.2007–
004333-42, local amendment for Munich University
Hospital 2242–03/08), and by the Ethics Committee of
ATTIKON University Hospital (approval 5/2008). Re-
search was performed in accordance to the Declaration
of Helsinki (ethical principles for medical research in-
volving human subjects). Samples of sepsis patients were
withdrawn immediately after diagnosis of sepsis and ad-
mission to the intensive care unit and before induction
of an antibiotic and/or steroid treatment. History of ma-
lignant diseases, immunodeficiency, age younger than
18 years, and previous corticosteroid or antibiotic ther-
apy were exclusion criteria. Patient characteristics are
listed in Tables 1, 2, 3, 4 and 5.
Blood cell isolation
After isolation of peripheral blood mononuclear cells
(PBMCs) by density centrifugation (Histopaque 1077,
Sigma-Aldrich, St. Louis, MO), T-cells were purified using
an AutoMACS Pro Separator (Cat. # 130–092-545, Milte-
nyi Biotec, Bergisch-Gladbach, Germany) and magnetic cell
separation (Pan T Cell Isolation Kit, Cat. # 130–096-535,
Miltenyi Biotec, Bergisch Gladbach, Germany), as to the
manufacturer’s recommendations. Cell number and viabil-
ity were assessed using a ViCell analyzer (Beckman Coulter,
Fullerton, CA). Only experiments exhibiting a cell viability
of more than 90% were included in our analyses. By apply-
ing untouched negative selection, binding of isolation beads
to T-cells and potential T-cell activation was avoided. Suc-
cesful T-cell isolation was confirmed by flow cytometry
analysis using a FTIC anti-human CD3 antibody (Cat. #
344804, BioLegend, San Diego, CA, USA). whole blood
Table 1 miRNA Microarray: Characteristics of Sepsis Patients
n 7
Gender (male/female) 3/4 (42.9%/ 57.1%)
Age, years (mean ± SD) 65.1 (± 13.4)
Septic Shock 4 (57.1%)
Sequential organ failure score (mean ± SD) 14.1 (± 3.5)
Nonsurvivors 3 (42.9%)
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analysis, PAXgene Blood RNA Tubes (PreAnalytiX, Hom-
brechtikon, Switzerland) were used according to the manu-
facturer’s instructions.
RNA-isolation
Total RNA was isolated from primary T-cells using the
mirVana miRNA Isolation Kit (Thermo Fisher Scientific,
Waltham, MA, USA) with subsequent DNase treatment
(Turbo DNase, Thermo Fisher Scientific, Waltham, MA,
USA). Total RNA from whole blood samples was purified
using the PAXgene Blood RNA Kit (PreAnalytiX, Hom-
brechtikon, Switzerland). The respective isolation proce-
dures followed the manufacturer’s instructions. Quantity
of total RNA was measured using a NanoDrop 2000 spec-
trophotometer (Thermo Fisher Scientific, Waltham, MA,
USA), quality was verified by an Agilent 2100 Bioanalyzer.
No differences in RNA quality/ quantity related to the age
of RNA samples could be detected. Storage of RNA has
been performed at − 80 °C. To further ensure stability of
miRNA over time, the same RNA samples independently
transcribed and analyzed in RT-qPCR in 2011, 2013 and
2017 have been depicted in Additional file 1: Figure S5.
miRNA microarray
RNA from seven patients and from seven controls was
used for miRNA microarray analysis (miRCURY LNA™
microRNA Array, Exiqon A/S, Vedbaek, Denmark), as to
the manufacturer’s recommendations.
Quantification of mRNA and miRNA expression
Expression of mRNAs and miRNAs was determined
using a LightCycler 480 instrument (Roche Diagnostics,
Mannheim, Germany) as described in (van der Heide et
al. 2016). In all reactions, equal amounts of RNA were
used (for miRNA transcription 6 ng of total RNA, for
mRNA transcription 1000 ng of total RNA). TaqMan as-
says and specifications for qPCR primer and probes are
given in Tables 6 and 7. Mean Target/Reference and
Target/Reference standard deviation has been calculated
for each miRNA/mRNA Target. Expression levels of sep-
tic patients are depicted relative to healthy control sub-
jects. Determination of quantification cycles has been
performed by the LightCycler software using the second
derivative maximum method. Quantification cycle (Cq)
cut-offs have been defined for miRNA (Cq 40) and
mRNA (Cq 35) quantification. Cq values beyond cut-offs
have been considered unspecific. For further validation
of microRNA expression, both miR-143 and miR-150 in
Pan T-cells and in whole blood cells have been assessed
using additional internal controls U44 and U48; results
are depicted in Additional file 2: Figure S1, Add-
itional file 3: Figure S2, Additional file 4: Figure S3 and
Additional file 5: Figure S4.
Statistical analysis
Student’s t-test or Mann-Whitney U tests, as appropri-
ate, served for comparisons. Normal distribution was
tested using the Kolmogorov-Smirnov test. The quanti-
fied array signals were background corrected (Normexp
with offset value 10 - Convolution model described by
Ritchie et al. (Ritchie et al. 2007)) and normalized using
the global Lowess (LOcally WEighted Scatterplot
Smoothing) regression algorithm. The obtained values
were further analyzed using two-sided Student’s t-test
and corrected via Benjamini-Hochberg False Discorvery
Rate (Benjamini and Hochberg 1995). A false discovery
value of less than 5% was considered significant.
Statistical analysis was performed using the statistical
software R (Developement Core Team 2008) and GraphPad
Prism 5.01 (GraphPad Software, Inc., USA). R 3.2.4 was
used for predictive modeling and Area-under-the-ROC
-curve (AUC) generation. All miRNAs that yielded signifi-
cant expression differences in T-cells were selected for pre-
dictive modeling. R’s step-function was used for step-wise
backward logistic regression on T-cell samples. AUCs were
visualized and generated using the R-package pROC, with
Table 2 T-cell samples: Characteristics of Sepsis Patients
n 31
Gender (male/female) 19/12 (61.2%/38.7%)
Age, years (mean ± SD) 57.2 (± 17.8)
Septic shock 14 (45.2%)
Sequential organ failure score (mean ± SD) 10.4 ± 5.4
Nonsurvivors 11 (35.5%)
Table 3 T-cell samples: Healthy controls
n 20
Gender (male/female) 12/8 (60%/40%)
Age, years (mean ± SD) 40.5 (± 5.5)
Healthy volunteers were all nonsmokers, without suspect of any acute or
chronical disease, blood count and electrolytes within normal limits
Table 4 Whole blood samples: Characteristics of Sepsis Patients
n 20
Gender (male/female) 13/7 (65%/35%)
Age, years (mean ± SD) 76.4 ± 6.0
Septic shock 11 (55%)
APACHE II Score (mean ± SD) 23,4 ± 7,9
Nonsurvivors 10 (50%)
Table 5 Whole blood samples: Healthy controls
n 10
Gender (male/female) 6/4 (60%/40%)
Age, years (mean ± SD) 77,8 ± 7,7
Healthy volunteers were age-matched ambulatory patients before elective
minor surgeries without suspect of severe chronical disease
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standard settings for bootstrapping. Vector artwork has
been designed using Adobe Illustrator CS5.1 (Adobe Sys-
tems Inc., San Jose, CA, USA). Data are depicted as me-
dian, 25th and 75th percentile and outliers, if not stated
otherwise. P values of less than 0.05 were defined as statisti-
cally significant (*p < 0.05; **p < 0.001).
Results
T-cells of septic patients exhibit a specific miRNA
signature pointing to immunoparalysis
To investigate if miRNAs could serve as biomarkers in-
dicative of immunoparalysis in sepsis, we performed a
miRNA microarray using RNA isolated from T-cells of
septic patients and from healthy individuals. As depicted
in Fig. 1a, 35 miRNAs were identified as being differen-
tially regulated in sepsis versus controls. Out of these,
eight miRNAs revealed p-values < 0.01. Importantly, for
all of them, a role in immunological processes has previ-
ously been described. The direction of regulation in our
array analysis strongly points towards immunosuppres-
sion: miR-150 and miR-342 - both regulators of pro-in-
flammatory processes (Robertson et al. 2016; Roderburg
et al. 2013) - were downregulated. Conversely, miR-15a,
miR-16, miR-93, miR-143, miR-223 and miR-424 - all
involved in anti-inflammatory signaling networks (Good-
win et al. 2015; Haneklaus et al. 2013; Honardoost et al.
2015; Liu et al. 2016; Zhao et al. 2014) - showed increased
expression levels.
To validate our findings, we analyzed the expression
levels of these miRNAs in a larger cohort of septic pa-
tients and healthy controls using TaqMan miRNA as-
says, which confirmed the initial array analysis (Fig. 1b):
The expression of pro-inflammatory miR-150 and
miR-342 was significantly reduced in septic T-cells,
whereas anti-inflammatory miR-15a, miR-16, miR-93,
miR-143, miR-223 and miR-424 showed markedly ele-
vated levels (for fold induction analysis see also Add-
itional file 6: Table S1). Taken together, our analysis of
T-cells from sepsis patients identified a signature of
eight differentially regulated miRNAs that - due to their
biological functions - might indicate an immunosuppres-
sive state.
Cytokine expression profile of septic T-cells indicates
immunoparalysis
To substantiate our assumption that the observed alter-
ations in miRNA expression patterns are associated with
immunoparalysis, we analyzed the expression of a set of
characteristic pro- and anti-inflammatory cytokines as
well as immune receptors relevant for T-cell immunity
in the same set of T-cell samples. Compared to healthy
controls, T-cells from septic patients showed signifi-
cantly reduced expression levels of T-cell growth and
survival factor interleukin 2 (IL-2), pro-inflammatory
cytokine receptor interleukin 7 receptor (IL-7R) and
inducible T-cell co-stimulator (ICOS) (Fig. 2a-c). Tran-
scripts of TH2-cytokines interleukin 4 (IL-4) and inter-
leukin 10 (IL-10) as well as Treg-differentiation
promoting transforming growth factor beta (TGF-β)
were markedly increased in sepsis samples (Fig. 2d-f ).
Collectively, we found expression patterns of cytokines,
inflammatory mediators and immune receptors that sug-
gest a state of immunoparalysis in T-cells of sepsis pa-
tients. These results were in line with the observed
miRNA pattern.
Table 6 TaqMan miRNA assays
Target Assay Nr.
U44 001094
U47 001223
U48 001006
hsa-mir-15a 000389
hsa-mir-16 000391
hsa-mir-93 001090
hsa-mir-143 002249
hsa-mir-150 000473
hsa-mir-223 002295
hsa-mir-342 002260
hsa-mir-424 000604
Table 7 qPCR primer and probes
Target/ Probe/ primer
direction
Primer sequence
SDHA #132 FW 5′-GAG GCA GGG TTT AAT ACA GCA-3′
SDHA #132 RV 5’-CCA GTT GTC CTC CTC CAT GT-3′
TBP #87 FW 5′-GAA CAT CAT GGA TCA GAA CAA CA-3′
TBP #87 RV 5′-ATA GGG ATT CCG GGA GTC AT-3′
IL-1β #41 FW 5’GAG GCA CAA GGC ACA ACA G-3‘
IL-1β #41 RV 5‘-CCA TGG CTG CTT CAG ACA C-3’
IL-2 #65 FW 5′-AAG TTT TAC ATG CCC AAG AAG G-3’
IL-2 #65 RV 5′-AAG TGA AAG TTT TTG CTT TGA GCT A-3’
IL-4 #38 FW 5’-TGC CTC ACA TTG TCA CTG C-3’
IL-4 #38 RV 5’-GCA CAT GCT AGC AGG AAG AAC-3’
IL-10 #67 FW 5’-TGC CTT CAG CAG AGT GAA GA-3’
IL-10 #67 RV 5’-GCA ACC CAG GTA ACC CTT AAA-3’
IL-7R #9 FW 5’-GCT TTT GAG GAC CCA GAT-3’
IL-7R #9 RV 5′ AGG CAC TTT ACC TCC ACG-3’
ICOS #2 FW 5’-TTC TGC TTG CGC ATT AAA GTT-3’
ICOS #2 RV 5’-CAT CTC ATA ATT GGC AGA ACC A-3’
TGF-β #31 FW 5‘-ACT ACT ACG CCA AGG AGG TCA C-3‘
TGF-β #31 RV 5‘-TGC TTG AAC TTG TCA TAG ATT TCG-3‘
FW forward primer, RV reverse primer; # probe number
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Fig. 1 (See legend on next page.)
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MicroRNA-223, microRNA-150 and microRNA-143 are
markers of immunosuppression in T-cells
To facilitate a potential clinical use, we next set out to
evaluate, whether single miRNAs out of the signature
might serve as surrogate marker for detection of sepsis-
associated immunosuppression in T-cells. To this end,
we used a variable selection procedure, focusing on
those miRNAs exhibiting the highest significance with
respect to differential expression in sepsis versus healthy
controls (miR-223, miR-150 and miR-143). The best
model for discrimination in T-cell samples displayed
miR-223 with an excellent area under the curve (AUC)
of 0.96 (95% CI: 0.9–1.0, Fig. 3). With AUCs of 0.91
(95% CI: 0.8–1.0) and 0.95 (95% CI: 0.88–1.0), miR-150
and miR-143 also revealed as very well performing
markers. We next crosschecked whether these three
(See figure on previous page.)
Fig. 1 Differential expression of miRNA in septic T-cells. a MicroRNA Microarray analysis. Heat map showing the differentially expressed miRNAs in
sepsis patients as compared to healthy controls, n = 7/7 (NC/Sepsis). RNA was isolated and miRNA array analysis was performed. Yellow colour
indicates upregulation of miRNA expression, red colour indicates decreased miRNA levels. b MiRNAs in human Pan T-cells of septic patients as
compared to healthy controls. Expression levels of miR-150, miR-342, miR-15a, miR-16, miR-93, miR-143, miR-223 and miR-424 in Pan T-cells of septic
patients and healthy controls were measured by TaqMan miRNA assays relative to U47. Data are shown as median, 25th and 75th percentile and
outliers, n = 10/20 (NC/Sepsis), performed in duplicates. Values represent expression relative to controls, *p < 0.05, **p < 0.001. Quantification cycle (Cq)
values for the single miRNAs were in the range of 21 (NC) and 23 (Sepsis) for miR-150, 24 (NC) and 26 (Sepsis) for miR-342, 30 (NC) and 29 (Sepsis) for
miR-15a, 23 (NC) and 22 (Sepsis) for miR-16, 30 (NC) and 28 (Sepsis) for miR-93, 34 (NC) and 29 (Sepsis) for miR-143, 26 (NC) and 22 (Sepsis) for miR-
223, 36 (NC) and 34 (Sepsis) for miR-424, respectively
Fig. 2 T-cell immunoparalysis in sepsis. Cytokine and immune receptor expression in T-cells of septic patients as compared to healthy controls. mRNA
levels of (a) IL-2, (b) IL-7R (c) ICOS, (d) IL-4, (e) IL-10 and (f) TGF-ß in Pan T-cells of septic patients and healthy controls, respectively, were measured by
qPCR relative to reference genes SDHA and TBP. Data are presented as median, 25th and 75th percentile and outliers, measurements were performed
in duplicates. Values represent expression relative to controls, *p < 0.05, **p < 0.001. Quantification cycle (Cq) values for the single cytokines and
receptors were in the range of 34 (NC) and 36 (Sepsis) for IL-2, 24 (NC) and 25 (Sepsis) for IL7R, 32 (NC) and 33 (Sepsis) for ICOS, 35 (NC) and 32 (Sepsis)
for IL-4, 35 (NC) and 33 (Sepsis) for IL-10, 25 (NC) and 24 (Sepsis) for TGF-ß, respectively
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miRNAs actually indicate impairment of adaptive im-
mune functions and found highly significant correlations
between the expression levels of these three miRNAs
and the T-cell specific markers of immunosuppression
IL7R and ICOS (miR-143: r = − 0.95 and − 0.78, p <
0.0005, miR-150: r = 0.87 and 0.66, p < 0.005, miR-223: r
= − 0,78 and − 0,64 p < 0.05), and, importantly, with
SOFA-scores (miR-143: 0.65, miR-150: − 0.7, miR-223:
0.57, p < 0.01; see also Table 8) Thus, we suggest that de-
termination of these miRNAs in T-cells provides a useful
method to assess immunoparalysis in sepsis.
T-cell specific expression profiles are largely masked in
whole blood samples
Purification of T-cells may be difficult to implement into
a clinical setting. A widely used approach to obtain pa-
tient’s immune cell samples for gene expression analysis
is the use of whole blood filter systems. While fast and
easy to handle, they contain a mixture of cells of innate
and adaptive immunity. It is therefore not clear, if T-cell
related immunosuppression can be detected in these
specimens.
We thus aimed to test, whether those miRNAs identified
as markers of T-cell immunosuppression might also per-
form sufficiently in whole blood samples. We first charac-
terized PAXgene samples of 20 sepsis patients and ten
healthy controls with respect to expression of the “im-
munosuppressive” miRNA signature and mRNA-levels of
anti-inflammatory IL4, IL10, TGF-ß and pro-inflammatory
“master cytokine” interleukin 1 beta (IL-1β). As shown in
Fig. 4a, pro-inflammatory miRNAs miR-150 and miR-342
in Paxgene samples were also diminished in patients with
sepsis as compared to healthy controls. Regarding anti-in-
flammatory miRNAs, only for miR-143 significant up-regu-
lation could be detected, whereas miR-16 and miR-93
exhibited markedly reduced levels and miR-15a, miR-223
and miR-424 showed no relevant alterations at all. Analysis
of cytokine expression (Fig. 4b) revealed significant
upregulation of pro-inflammatory IL-1β but also of anti-in-
flammatory TGF-β. TH2-cytokines showed disparate results
as well: IL-4 was downregulated, while IL-10 was
upregulated.
Taken together, neither a distinct pro- nor anti-
inflammatory miRNA/cytokine signature could be detected
Fig. 3 Discriminatory power of miR-143, miR-150 and miR-223 in T-cells. Predictive modeling and Area-under-the-ROC-curve generation. Candidate
miRNAs were selected for predictive modeling: (a) miR-143, (b) miR-150 and (c) miR-223 in T-cells of septic patients as compared to healthy controls,
n = 10/20 (NC/Sepsis). The shadowed areas denote the confidence interval for the area under the curve
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in whole blood samples. Since whole blood consists of a
mixture of innate and adaptive immune cells - with neutro-
phils and lymphocytes accounting for a share of approxi-
mately 50% and 40%, respectively - miRNA and cytokine
expression is likely to represent a net result of simultan-
eously occurring hyper- and hypoinflammation evoked by
both innate and adaptive immunity.
In whole blood samples, miR-143 and miR-150 can serve
as markers of T-cell immunosuppression
Still aiming to use whole blood samples for detection of
immunosuppression, we hypothesized that it might be a
promising approach to focus on miRNAs that i.) are dif-
ferentially regulated in the same direction in both sam-
ple types, and ii.) exhibit markedly lower expression
levels in PAXgene samples than in T-cells. In these
cases, polymorphonuclear cells (PMN) would not signifi-
cantly contribute to the expression level of the respective
miRNA in whole blood samples. Consequently, the ef-
fect seen in T-cells would – albeit diluted – be visible
also in whole blood.
These criteria were met by miR-143, miR-150 and
miR-342 (Figs. 4a and 5b). Using a variable selection
procedure, miR-143 and miR-150 revealed a strong dis-
criminative power (AUCs 0.88 (95% CI: 0.74–1.0) and
0.95 (95% CI: 0.9–1.0), Fig. 5a). MiR-223, the best per-
forming marker in T-cells, was not differentially regu-
lated and – as a typical innate miRNA – was found to
be strongly expressed in PAXgene samples. Conse-
quently, the resulting AUC was 0.66 (95% CI: 0.44–0.87,
Fig. 5a), thus revealing miR-223 being not suitable as a
biomarker for immunoparalysis in whole blood samples.
In summary, we suggest that whole blood analysis of
miR-143 and miR-150 might be a promising strategy for
the detection of T-cell immunosuppression in sepsis.
Discussion
The dynamics of immune reactions during sepsis has long
been regarded as a linear sequence of an initial hyperin-
flammatory phase followed by prolonged immunosup-
pression. Recent research, however, has revealed a more
complex immunopathology: It is clear now that sepsis is a
condition of constant immune dysfunction with alternat-
ing periods of pro- and anti-inflammatory predominance
(Boomer et al. 2014), where hyperinflammation is mainly
driven by innate immune cells, whereas immunoparalysis
is a characteristic reaction of the adaptive immune system
(Xiao et al. 2011; Hotchkiss et al. 2013). Immunosuppres-
sion has turned out the leading cause of death in sepsis
(Boomer et al. 2011). While modern treatment concepts
of sepsis are often capable to control hyperinflammation,
therapy of immunoparalysis remains difficult and reliable
methods allowing its early detection are lacking. In this
situation, identification of miRNAs that are suitable to
serve as biomarkers of a compromised immunity might be
a promising approach.
We here identified a miRNA signature of eight differ-
entially expressed miRNAs in T-cells of sepsis patients,
which are indicative of sepsis-associated immunoparaly-
sis. Of these miRNAs, miR-143 and miR-150 also per-
formed well in whole blood samples: With AUCs of 0.88
(95% CI: 0.74–1.0) and 0.95 (95% CI: 0.9–1.0), respect-
ively, they may even serve as surrogate biomarkers to as-
sess septic T-cell immunoparalysis in a clinical setting,
where the selection of T-cells is not feasible. These find-
ings may open up new diagnostic perspectives for septic
immune dysfunction.
MiRNAs offer unique features, which render them at-
tractive as clinical biomarkers: They are expressed in
disease-specific patterns, they are remarkably stable –
even when released extracellularly – and they can easily
be detected in virtually all tissues and body fluids (Benz
et al. 2016). A considerable number of studies investigat-
ing miRNAs as biomarker in sepsis have been published
in the last few years. In these studies, the expression of
miRNAs was profiled in various tissue samples (plasma/
serum/whole blood/purified blood cells) (Ho et al. 2016).
Results, however, were heterogeneous with significant
differences in expression profiles, e.g. miR-15/− 16
(Goodwin et al. 2015; Wang et al. 2012a; Wang et al.
2014a; Wang et al. 2015; Wang et al. 2012b; Wang et al.
2012c; Wang et al. 2014b), miR-146 (Wang et al. 2010;
Wu et al. 2014; Wang et al. 2013), miR-150 (Roderburg
et al. 2013; Vasilescu et al. 2009; Ma et al. 2013) and
miR-223 (Wang et al. 2012a; Wang et al. 2015; Wang et
al. 2012c; Wang et al. 2010). Thus, commonly accepted
sepsis biomarkers are yet to be identified, in particular
with respect to the discrimination between the hyperin-
flammatory and the immunoparalytic phase of the syn-
drome. As different types of human immune cells
express cell-type-specific “miRNomes” (Leidinger et al.
2014; Ludwig et al. 2016; Wang et al. 2012d), evaluation
of miRNAs as sepsis biomarkers in whole blood samples,
serum, plasma or PBMCs is likely to yield mixtures of
expression patterns. Moreover, a potential release of
different miRNA signatures by acute or chronic co-mor-
bidities may further hamper the diagnostic values of
these approaches (Chen et al. 2008).
We aimed at avoiding such confounders by directly
assessing the miRNA expression profile in T-cells using
Table 8 correlation analysis miR-143, −150, −223
ICOS IL7R SOFA
r p r p r p
miR-143 −0,78 < 0,0005 −0,95 < 0,0005 0,65 < 0,01
miR-150 0,66 < 0,005 0,87 < 0,005 −0,7 < 0,01
miR-223 −0,64 < 0,05 −0,78 < 0,05 0,57 < 0,01
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a whole transcriptome approach, and detected eight
highly differentially expressed miRNAs, which were sub-
sequently validated in a larger cohort of sepsis patients
by qPCR. The observed miRNA expression strongly in-
dicates a state of immunosuppression: MiR-150 and
miR-342, both exerting proinflammatory action, were
markedly downregulated. While miR-150 targets IL-10
and IL-18 in leukocytes, microRNA-342 contributes to
broad host cell immunity against infection (Robertson et
al. 2016). Also, low serum levels of miR-150 in critically ill
patients have been associated with an unfavourable out-
come, and miR-150has been discusssed as prognostic
Fig. 4 Simultaneous hyper- and hypoinflammation in whole blood of septic patients. a MiRNA expression in human whole blood obtained from
septic patients as compared to healthy controls. Expression levels of miR-150, miR-342, miR-15a, miR-16, miR-93, miR-143, miR-223 and miR-424
were assessed by TaqMan miRNA assays relative to U47. Data are shown as median, 25th and 75th percentile and outliers, n = 10/20 (NC/Sepsis)
performed in duplicates. Values represent expression relative to controls, *p < 0.05, **p < 0.001. Quantification cycle (Cq) values for the single
miRNAs were in the range of 24 (NC) and 26 (Sepsis) for miR-150, 26 (NC) and 27 (Sepsis) for miR-342, 30 (NC) and 31 (Sepsis) for miR-15a, 21
(NC) and 23 (Sepsis) for miR-16, 26 (NC) and 29 (Sepsis) for miR-93, 34 (NC) and 33 (Sepsis) for miR-143, 21 (NC and Sepsis) for miR-223, 40 (NC)
and 39 (Sepsis) for miR-424, respectively. b Cytokine expression in human whole blood obtained from septic patients as compared to healthy
controls. mRNA levels of IL-4, IL-1β, IL-10 and TGF-β were measured by qPCR relative to reference genes SDHA and TBP. Data are shown as
median, 25th and 75th percentile and outliers, n = 10/20 (NC/Sepsis) performed in duplicates. Values represent expression relative to controls, *p
< 0.05, **p < 0.001. Quantification cycle (Cq) values for the single cytokines and receptors were in the range of 32 (NC) and 35 (Sepsis) for IL-4, 27
(NC and Sepsis) for IL-1β, 35 (NC) and 32 (Sepsis) for IL-10, 24 (NC) and 25 (Sepsis) for TGF-β, respectively
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marker (leukocytes and plasma) and for discrimination be-
tween sepsis and SIRS (whole blood) (Roderburg et al. 2013;
Vasilescu et al. 2009; Ma et al. 2013). The detected downreg-
ulation of both miRNAs thus may lead to a restriction of
T-cell effector functions. Six further miRNAs – miR-15a,
miR-16, miR-93, miR-143, miR-223 and miR-424, mainly
exhibiting anti-inflammatory or anti-proliferative functions
– were upregulated in septic T-cells. MiR-15a and miR-16
Fig. 5 Discriminatory power of miR-143 and miR-150 in whole blood. a Predictive modeling and Area-under-the-ROC-curve generation.
Candidate miRNAs were selected for predictive modeling: miR-143, miR-150 and miR-223 in whole blood samples of septic patients compared to
healthy controls, n = 10/20 (NC/Sepsis). The shadowed areas denote the confidence interval for the area under the curve. b MiRNA quantification
cycles of human CD4+ T-cells and whole blood cells. Samples of septic patients and healthy controls were measured, n = 10/20 (NC/Sepsis),performed
in duplicates. Equal amounts of RNA were used to determine quantification cycles of miR-143, miR-150, miR-223 and miR-342 by TaqMan miRNA
assay. Data are shown as median, 25th and 75th percentile and outliers
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have been shown to downregulate NF-κB signaling
pathways and to reduce pro-inflammatory cytokine
production in T-cells via downregulation of CXCL10
(Goodwin et al. 2015; Liu et al. 2016). Moreover, they
are known to exert pro-apoptotic effects in lympho-
cytes and granulocytes (Precone et al. 2013). MiR-93 is
proposed to suppress TH17-cells (Honardoost et al.
2015), whereas miR-143 was reported to exhibit im-
munosuppressive functions via targeting COX-2 and
TAK-1 (Zhao et al. 2014) and has been suggested as
biomarker to distinguish between sepsis and SIRS (Han
et al. 2016). (Zhao et al. 2014). MicroRNA-223 is inter-
fering with several important inflammatory pathways,
e.g. STAT1/3,NF-κB, and controls the NLRP3 inflam-
masome (Haneklaus et al. 2013). Collectively, upregula-
tion of these miRNAs is likely to contribute to an
immunosuppressive state.
Hallmarks of immunosuppression during sepsis have
been defined in recent studies (Hamers et al. 2015):
Lymphocytes express altered cytokine expression pro-
files with reduced levels of pro-inflammatory cytokines,
enhanced production of anti-inflammatory cytokines
(e.g. IL-10 and TGF-β), and receptor expression pat-
terns favoring inhibitory receptors (Boomer et al. 2012;
Gogos et al. 2000). Moreover, increased apoptosis rates,
diminished IL-7 receptor expression and low levels of
IL-2, indicating a reduced proliferative potential, have
been found (Lang et al. 2005; Wherry and Kurachi
2015). In line with these data, we detected increased
levels of anti-inflammatory cytokines IL-4, IL-10 and
TGF-β as well as a reduction of IL-7R in isolated
T-cells of sepsis patients, indicating a compromised
T-cell immune status. Also, a substantial loss of IL-2
mRNA and diminished levels of T-cell inflammatory re-
sponse regulation factor ICOS clearly suggest reduced
survival and activity of effector T-cells (Boomer et al.
2014; Hotchkiss et al. 2013; Wikenheiser and Stumho-
fer 2016). Thus, in all sepsis patients, signs of immuno-
paralysis within the adaptive immunity could be
detected. The extent, however, was inter-individually
different and quantification of immunosuppression may
provide valuable information to assess the actual state
of the individual patient - also during the course of the
disease - and to define optimal treatment strategies. In
this dynamic situation, our miRNA signature could be
a fast and reliable tool.
As requirement for simultaneous quantification of
eight miRNAs might impede the clinical use of our
approach, we next aimed at identifying key markers of
immunosuppression. Indeed, miR-223, miR-143 and
miR-150 exhibited an outstanding predictive power with
AUCs of 0.96, 0.95 and 0.90. Importantly, these miRNAs
significantly correlated with T-cell specific markers of
immunosuppression and with SOFA scores. Therefore,
all three miRNAs might be potential candidates to evalu-
ate T-cell associated immunoparalysis in sepsis.
Even when limited to measurement of single miRNAs
with sufficient discriminatory power, a T-cell-based
approach may not be feasible in a clinical routine situ-
ation. In this setting, the commonly applied method is
the use of filter systems, enabling a fast and easy-to-han-
dle approach to obtain patient’s blood samples for gene
expression analyses. It has to be kept in mind, however,
that these filters retain a mixture of both innate and
adaptive immune cells (with PMN, T-cells, and Mono-
cytes making up for the largest shares of cells with 50%,
40%, and 10%) and it therefore is not clear, whether
T-cell immunoparalysis is assessable in these samples. In
our analyses, indeed, cytokine and miRNA expression
profiles exhibited signs of both immune activation and
suppression, which is likely to represent the net result of
simultaneously occurring but divergent activation pat-
terns of innate and adaptive immune cells, thereby
masking T-cell specific effects. These findings are in line
with previous studies showing that human leukocytes
during sepsis do not express distinct pro- or anti-inflam-
matory profiles (Tang et al. 2010). Notwithstanding that,
we assumed that innate immune cells would not signifi-
cantly impair the diagnostic use of T-cell specific miR-
NAs in whole blood samples, if the expression levels of
the respective miRNAs in PMN and Monocytes were
markedly lower compared to T-cells. Indeed, we identi-
fied miR-143 and miR-150 as extremely well performing
markers indicative of T-cell immunosuppression not
only in T-cells but also in PAXgene samples: They were
differentially regulated in the same direction in both
sample types, they exhibited low expression levels in in-
nate cells and - after applying a variable selection pro-
cedure - they showed excellent discriminatory power
with AUCs of 0.88 and 0.95, respectively, also in PAX-
gene samples. Nevertheless, biases caused by larger shifts
in lymphocyte numbers may occur when using PAX-
gene. As we included both immunosuppressive (upregu-
lated) miR-143 and proinflammatory (downregulated)
miR-150 into our analyses, such distortions could easily
be detected. In our series, however, this phenomenon
was not observed.
Medical and ethical restriction have limited the
spectrum of possible molecular analyses of this pilot
study:
1. We could only analyze mRNA and miRNA
expression levels, additional analysis of protein
levels or quantification of T-cell surface markers
was not possible. However, as reported in a
recent study, mRNA levels of the most relevant
cytokines in activated T cells are translated into
comparable protein levels (Mohnle et al. 2015).
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2. We were only able to investigate Pan T-cells, which
did not allow specifying septic T-cell immunopara-
lysis with respect to T-cell subsets. However, rela-
tively stable CD4/CD8 ratios and unaltered CD4+
proportions in peripheral blood during sepsis have
been described in several studies (Francois et al.
2018; Inoue et al. 2014).
3. Both patient groups differ in age, since the samples
have been provided from ICUs of different countries
and with different clinical focus. However, we
analyzed the study cohorts independently with
respect to the validity of our T cell miRNA markers.
Remarkably, despite different age-distributions, both
miR-143 and miR-150 performed comparably well in
either group thus indicating age-independency.
4. Sampling of patients was performed over a long
course of time. However, as microRNA is known
for its outstanding stability (Jung et al. 2010; Mraz
et al. 2009), bias due to sample degradation is
unlikely. Furthermore, storage has been performed
properly, RNA analysis showed no major differences
in quality or quantity related to the age of RNA
samples and additional RT-qPCR analyses revealed
no significant alterations in microRNA level over
time (Additional file 1: Figure S5).
Conclusions
Efficient therapeutic interventions in septic patients are
currently hampered by a lack of reliable biomarkers for
diagnosis of sepsis-associated immune dysfunction. Our
pilot study identifies miR-143 and miR-150 as candidate
markers for detection of T-cell immunosuppression and
thus contributes to the development of innovative strat-
egies using miRNAs as biomarkers of a compromised im-
mune status during sepsis. Importantly, these markers can
be determined in whole blood samples, which facilitates a
future clinical use. Large-scale, multicenter, prospective
evaluations are now required to further elaborate our
diagnostic approach and to enable its implementation into
clinical routine.
Additional files
Additional file 1: Figure S5. U47 Quantification cycles for samples
analyzed in 2011, 2013 and 2017. Quantification cycles of U47 in (A)
healthy controls and (B) septic patients were measured by TaqMan
miRNA assays. The same RNA samples have been used for independent
transcription and RT-qPCR analysis in the years 2011, 2013 and 2017, all
experiments performed in duplicates. (EPS 1313 kb)
Additional file 2: Figure S1. Expression of microRNA-143 in T-cell sam-
ples using additional internal controls. Expression levels of miR-143 in Pan
T-cells of septic patients and healthy controls were measured by TaqMan
miRNA assays relative to (A) U44, (B) U47, (C) U48 and (D) U44/U47/U48.
Data are shown as median, 25th and 75th percentile and outliers, n = 5/
10 (NC/Sepsis), performed in duplicates. Values represent expression
relative to controls, *p < 0.05, **p < 0.001. (EPS 747 kb)
Additional file 3: Figure S2. Expression of microRNA-150 in T-cell
samples using additional internal controls. Expression levels of miR-150 in
Pan T-cells of septic patients and healthy controls were measured by Taq-
Man miRNA assays relative to (A) U44, (B) U47, (C) U48 and (D) U44/U47/
U48. Data are shown as median, 25th and 75th percentile and outliers, n
= 5/10 (NC/Sepsis), performed in duplicates. Values represent expression
relative to controls, *p < 0.05, **p < 0.001. (EPS 749 kb)
Additional file 4: Figure S3. Expression of microRNA-143 in whole
blood samples using additional internal controls. Expression levels of
miR-143 in whole blood cells of septic patients and healthy controls were
measured by TaqMan miRNA assays relative to (A) U44, (B) U47, (C) U48
and (D) U44/U47/U48. Data are shown as median, 25th and 75th
percentile and outliers, n = 5/10 (NC/Sepsis), performed in duplicates.
Values represent expression relative to controls, *p < 0.05, **p < 0.001.
(EPS 746 kb)
Additional file 5: Figure S4. Expression of microRNA-150 in whole blood
samples using additional internal controls. Expression levels of miR-150 in
whole blood cells of septic patients and healthy controls were measured by
TaqMan miRNA assays relative to (A) U44, (B) U47, (C) U48 and (D) U44/U47/
U48. Data are shown as median, 25th and 75th percentile and outliers, n =
5/10 (NC/Sepsis), performed in duplicates. Values represent expression
relative to controls, *p < 0.05, **p < 0.001. (EPS 734 kb)
Additional file 6: Table S1. Fold difference miRNA expression in T-cells
of septic patients compared to healthy controls. Table S2. Positive and
negative predictive values for miR-143/− 150/ -223. Table S3. Benjamini-
Hochberg correction: p-value and false discovery rate. (DOCX 19 kb)
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